Methylphenidate Teva

Methylphenidate hydrochloride, the active ingredient in Methylphenidate Teva, is a central nervous system stimulant presented as an oral tablet for oral use. It treats attention deficit hyperactivity disorder and narcolepsy in children, adolescents and adults. GNH USA supplies Methylphenidate Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methylphenidate Teva is a central nervous system stimulant indicated for the following conditions:

- Attention deficit hyperactivity disorder (children): improves concentration, reduces hyperactivity and impulsivity. - Attention deficit hyperactivity disorder (adults): enhances focus and functional performance in daily activities. - Narcolepsy: decreases excessive daytime sleepiness and improves wakefulness.

Methylphenidate may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced food intake, especially in children. - Headache: mild to moderate intensity. - Stomach pain or nausea: gastrointestinal discomfort. - Increased heart rate: mild tachycardia. - Irritability or mood swings.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, arrhythmia, or chest pain. - Psychotic symptoms: hallucinations or delusional thinking. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Motor or vocal tics: involuntary movements or sounds. - Growth suppression: reduced height velocity in children. - Priapism: prolonged painful erection.

Before prescribing Methylphenidate, clinicians should consider several safety measures.

- Cardiovascular assessment: evaluate blood pressure and heart history. - Growth monitoring: regularly measure height and weight in pediatric patients. - Allergy screening: avoid use in individuals with known hypersensitivity to methylphenidate. - Drug interaction review: use caution with MAO inhibitors and antihypertensives. - Discontinuation plan: taper dose rather than abrupt stop to reduce withdrawal effects. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Methylphenidate can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: may increase cardiovascular side effects. - Antihypertensive agents: can diminish blood‑pressure‑lowering effect.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may raise methylphenidate levels. - Antacids: can alter gastrointestinal absorption. - Alcohol: may enhance central nervous system stimulation.